Cosmo Pharmaceuticals' 2025 recurring revenue rises, proposes dividend

Cosmo NV

09/03/2026 06:11

Overview

Ireland-based life sciences firm's 2025 revenue of €104.2 mln aligns with company guidance

EBITDA of €9.5 mln exceeded upper end of company guidance

Company proposes €2.10 per share dividend

Outlook

Cosmo expects 2026 total revenues of €105 to 110 million

Company anticipates 2026 recurring revenues of €98 to 102 million

Cosmo projects 2026 EBITDA of €10.5 to 13.5 million

Result Drivers

RECURRING REVENUE GROWTH - Recurring revenues grew 15% year-over-year, driven by GI Genius™ and Winlevi® expansion

COST REDUCTION - Operating expenses decreased 6% year-over-year due to efficiency measures and normalization

EBITDA EXCEEDS GUIDANCE - EBITDA of €9.5 mln exceeded the upper end of company guidance, aided by cost control and operating leverage

Company press release: ID:nNFC80LPTz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-EUR 0.23
FY EBITDA
EUR 9.52 mln
FY Gross Profit
EUR 50.56 mln
FY Operating Expenses
-EUR 53.79 mln
FY Operating Income
-EUR 3.24 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Cosmo Pharmaceuticals NV is CHF130.00, about 21% above its March 6 closing price of CHF107.40

The stock recently traded at 101 times the next 12-month earnings vs. a P/E of 29 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)